# DeLLpro-300 (NCT04702737)

> A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: tarlatamab
- Indication: de novo or treatment emergent neuroendocrine prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04702737
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Neuroendocrine Prostate Cancer
- Interventions: Tarlatamab
- Enrollment: 41
- Primary outcome: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)
- Primary outcome: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)

## Indexed commentary on DeLLpro-300 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dellpro-300-nct04702737